Takeda Pharmaceutical Dividends and Buybacks
Dividend criteria checks 5/6
Takeda Pharmaceutical is a dividend paying company with a current yield of 4.54%. Next payment date is on 27th June, 2025 with an ex-dividend date of 28th March, 2025.
Key information
4.5%
Dividend yield
0.03%
Buyback Yield
Total Shareholder Yield | 4.6% |
Future Dividend Yield | 4.9% |
Dividend Growth | 0.3% |
Next dividend pay date | 27 Jun 25 |
Ex dividend date | 28 Mar 25 |
Dividend per share | n/a |
Payout ratio | 145% |
Recent dividend and buyback updates
Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Mar 18Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥98.00
Mar 03Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Jan 30Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥98.00
Dec 31Recent updates
These 4 Measures Indicate That Takeda Pharmaceutical (TSE:4502) Is Using Debt Reasonably Well
May 07Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Mar 18Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥98.00
Mar 03Earnings Tell The Story For Takeda Pharmaceutical Company Limited (TSE:4502)
Feb 27The Strong Earnings Posted By Takeda Pharmaceutical (TSE:4502) Are A Good Indication Of The Strength Of The Business
Feb 06Takeda Pharmaceutical Company Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Jan 30Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥98.00
Dec 31Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Dec 17Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Dec 03Here's Why Takeda Pharmaceutical (TSE:4502) Can Manage Its Debt Responsibly
Nov 25Tactical Innovation And Global Expansion To Propel Growth Amid Market Challenges
Nov 07 Anticipated efficiency gains and strategic expansions are expected to boost profit margins and revenue through new product launches and market share growth.Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 04Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00
Sep 24Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E
Sep 20Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Aug 08Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 02Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00
Jul 25Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Jul 11Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year
Jun 30Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt
Jun 11Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings
May 21Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next
May 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 4502's dividends per share have been stable in the past 10 years.
Growing Dividend: 4502's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
Takeda Pharmaceutical Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (4502) | 4.5% |
Market Bottom 25% (JP) | 1.9% |
Market Top 25% (JP) | 3.9% |
Industry Average (Pharmaceuticals) | 2.5% |
Analyst forecast (4502) (up to 3 years) | 4.9% |
Notable Dividend: 4502's dividend (4.54%) is higher than the bottom 25% of dividend payers in the JP market (1.88%).
High Dividend: 4502's dividend (4.54%) is in the top 25% of dividend payers in the JP market (3.94%)
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (145.4%), 4502's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (37.3%), 4502's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/07 04:34 |
End of Day Share Price | 2025/05/07 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Takeda Pharmaceutical Company Limited is covered by 39 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Atsushi Seki | Barclays |
Koichi Mamegano | BofA Global Research |
Hazim Bahari | CFRA Equity Research |